帕博利珠单抗对比化疗治疗微卫星高度不稳定或错配修复缺陷转移性结直肠癌:随机III期KEYNOTE-177研究5年随访
KEYNOTE-177 III期研究5年随访显示,在未治疗的MSI-H/dMMR转移性结直肠癌患者中,帕博利珠单抗组中位总生存77.5个月 vs 化疗组36.7个月(HR 0.73,95%CI 0.53-0.99),5年OS率54.8% vs 44.2%;中位无进展生存16.5 vs 8.2个月(HR 0.60,95%CI 0.45-0.79)。帕博利珠单抗组不良事件更少(80% vs 99%;3-5级22% vs 67%)。帕博利珠单抗仍是MSI-H/dMMR转移性结直肠癌的标准治疗。
要点
- 帕博利珠单抗组中位OS 77.5个月 vs 化疗组36.7个月(HR 0.73,95%CI 0.53-0.99)。
- 帕博利珠单抗组中位PFS 16.5个月 vs 化疗组8.2个月(HR 0.60,95%CI 0.45-0.79)。
- 帕博利珠单抗组不良事件80% vs 化疗组99%;3-5级22% vs 67%。
核心结论
- 中位随访73.3个月时,帕博利珠单抗组中位OS为77.5个月,化疗组为36.7个月(HR 0.73,95%CI 0.53-0.99),尽管有效交叉率为62%。
- 帕博利珠单抗组中位PFS为16.5个月,化疗组为8.2个月(HR 0.60,95%CI 0.45-0.79)。
- 帕博利珠单抗组中位缓解持续时间为75.4个月(范围2.3+至80.1+个月),化疗组为10.6个月(范围2.8至71.5+个月)。
- 帕博利珠单抗仍是MSI-H/dMMR转移性结直肠癌的标准治疗。
研究设计与样本
- III期KEYNOTE-177随机研究,纳入未治疗的MSI-H/dMMR转移性结直肠癌成人患者,按1:1随机分配接受帕博利珠单抗200 mg静脉每3周一次或化疗。
- 化疗组患者在中枢确认疾病进展后可交叉接受帕博利珠单抗;共307例患者随机分配至帕博利珠单抗组(n=153)或化疗组(n=154)。
- 双主要终点为按RECIST v1.1评估的PFS和OS;次要终点包括缓解持续时间和安全性。
- 数据截止日期为2023年7月17日,中位随访73.3个月(范围64.9-89.2个月)。
主要发现
- 帕博利珠单抗组中位OS为77.5个月 vs 化疗组36.7个月(HR 0.73,95%CI 0.53-0.99);5年OS率分别为54.8% vs 44.2%。
- 帕博利珠单抗组中位PFS为16.5个月 vs 化疗组8.2个月(HR 0.60,95%CI 0.45-0.79)。
- 帕博利珠单抗组中位缓解持续时间为75.4个月(范围2.3+至80.1+个月) vs 化疗组10.6个月(范围2.8至71.5+个月)。
- 化疗组57例(37.0%)按方案交叉至帕博利珠单抗,39例(25.3%)方案外接受PD-(L)1抑制剂,有效交叉率为62%。
- 帕博利珠单抗组不良事件发生率为80% vs 化疗组99%;3-5级不良事件分别为22% vs 67%。
关键数值与推荐
- MSI-H/dMMR转移性结直肠癌一线治疗:帕博利珠单抗200 mg静脉每3周一次。
- 帕博利珠单抗组中位OS 77.5个月 vs 化疗组36.7个月(HR 0.73,95%CI 0.53-0.99)。
- 帕博利珠单抗组中位PFS 16.5个月 vs 化疗组8.2个月(HR 0.60,95%CI 0.45-0.79)。
- 帕博利珠单抗组5年OS率54.8% vs 化疗组44.2%。
- 帕博利珠单抗组中位缓解持续时间75.4个月(范围2.3+至80.1+个月) vs 化疗组10.6个月(范围2.8至71.5+个月)。
临床怎么用
- 帕博利珠单抗仍是MSI-H/dMMR转移性结直肠癌的标准治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Results from the phase III KEYNOTE-177 study established pembrolizumab as a new first-line standard of care for microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). Previous results from KEYNOTE-177 showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with pembrolizumab versus chemotherapy ± bevacizumab/cetuximab in MSI-H/dMMR mCRC. Results after >5 years of follow-up are reported. PATIENTS AND METHODS: Adults with untreated MSI-H/dMMR mCRC were randomly assigned 1 : 1 to receive pembrolizumab 200 mg intravenously every 3 weeks or chemotherapy. Patients assigned to chemotherapy could cross over to pembrolizumab after centrally confirmed progressive disease. Dual primary endpoints were PFS per RECIST v1.1 and overall survival (OS). Secondary endpoints included duration of response and safety. RESULTS: At data cut-off (17 July 2023), median follow-up was 73.3 months (range, 64.9-89.2 months). Overall, 307 patients were assigned to receive pembrolizumab (n = 153) or chemotherapy (n = 154). Fifty-seven (37.0%) patients assigned to chemotherapy crossed over to pembrolizumab per protocol; 39 (25.3%) received a programmed cell death protein 1/programmed death-ligand 1 [PD-(L)1] inhibitor off protocol (effective crossover rate, 62%). Median OS was 77.5 months with pembrolizumab versus 36.7 months with chemotherapy (hazard ratio, 0.73; 95% confidence interval 0.53-0.99); 5-year OS rates were 54.8% versus 44.2%. Median PFS was 16.5 months with pembrolizumab and 8.2 months with chemotherapy (hazard ratio, 0.60; 95% confidence interval 0.45-0.79). Median duration of response was 75.4 months (range, 2.3+ to 80.1+ months) with pembrolizumab versus 10.6 months (range, 2.8 to 71.5+ months) with chemotherapy. Compared with chemotherapy, fewer patients in the pembrolizumab arm experienced adverse events (80% versus 99%; grade 3-5, 22% versus 67%). CONCLUSIONS: With >5 years of follow-up, responses to pembrolizumab remained durable. Median OS was more than twice as long in patients treated with pembrolizumab versus chemotherapy in first line despite an effective crossover rate of 62%. Pembrolizumab remains a standard of care for MSI-H/dMMR mCRC.
引用
- André T, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study. Ann Oncol. 2024. PMID: 39631622. doi:10.1016/j.annonc.2024.11.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。